Annual report pursuant to Section 13 and 15(d)

NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details 7)

v3.3.1.900
NATURE OF OPERATIONS AND SIGNIFICANT ACCOUNTING POLICIES (Details 7)
$ / shares in Units, shares in Thousands, $ in Millions
Aug. 25, 2014
USD ($)
director
$ / shares
shares
Jun. 26, 2014
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Premium to Entity Average Stock Price for the Trailing Thirty Day Period   10.00%
Fosun Pharma [Member]    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Shares, Issued | shares 2,855  
Share Price | $ / shares $ 16.19  
Period of Time to Measure Premium of Entity Common Stock   30 days
Related Party Ownership Percentage After Common Stock Purchase 15.00%  
Common Stock    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Dividends Payable, Amount Per Share | $ / shares $ 1.50  
Dividends payable to shareholders $ 28.5  
Common Stock | Fosun Pharma [Member]    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Proceeds from Issuance of Private Placement $ 44.8  
China Joint Venture [Member]    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions 80.00%  
Initial Capitalization Amount $ 20.0  
China Joint Venture [Member] | Fosun Pharma [Member]    
Strategic Alliance and Formation of China Joint Venture [Line Items]    
Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions 20.00%  
Initial Capitalization Amount $ 16.0  
Number of Board of Directors Initially Appointed | director 1